Serum VEGF, SIL-2R and HGF in Patients with Primary HCC before and after Percutaneous Microwave Coagulation

Primary hepatocellular carcinoma (HCC) is one of the most commonly-encountered malignant tumors in the world (Abdelgawad et al., 2013; Berk et al., 2013; Chittmittrapap et al., 2013; Gupta et al., 2013; Norsa’adah et al., 2013; Hao et al., 2013; Zekri et al., 2013; Zhu et al., 2013; Cai et al., 2014; El Kassas et al., 2014; Fan et al., 2014; Ji et al., 2014; Jeng et al., 2014; Li et al., 2014; Tang et al., 2014; Wang et al., 2014; Zhang et al., 2014). Most small liver cancers (single and diameter ≤5 cm) are in the early stage of liver cancer development, which is crucial to treat the liver cancer in clinic. At present, percutaneous microwave coagulation therapy (PMCT) as a minimally-invasive treatment can technically inactivate the small liver cancer with the diameter ≤5 cm completely one time. Modern imaging examinations have been able to reflect the real situation of tumor tissue necrosis timely, but it still needs to find its hematologic monitoring index (Zhan et al., 2013). In clinic, we are hoping to find a good repeatable, convenient and effective hematologic evaluation index that can